Feng Y - Search Results

1

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma.

Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Feng Y, et al. Br J Clin Pharmacol. 2014 Jul;78(1):106-17. doi: 10.1111/bcp.12323. Br J Clin Pharmacol. 2014. PMID: 24433434 Free PMC article. Clinical Trial.

2

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Feng Y, et al. Br J Clin Pharmacol. 2008 Nov;66(5):629-39. doi: 10.1111/j.1365-2125.2008.03276.x. Epub 2008 Jul 31. Br J Clin Pharmacol. 2008. PMID: 18771484 Free PMC article.

3

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Komoroski B, et al. Among authors: feng y. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Clin Pharmacol Ther. 2009. PMID: 19129749 Clinical Trial.

4

Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.

Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Leil TA, et al. Among authors: feng y. Clin Pharmacol Ther. 2010 Sep;88(3):375-82. doi: 10.1038/clpt.2010.106. Epub 2010 Aug 4. Clin Pharmacol Ther. 2010. PMID: 20686477

5

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Feng Y, et al. Clin Cancer Res. 2013 Jul 15;19(14):3977-86. doi: 10.1158/1078-0432.CCR-12-3243. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741070

6

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.

Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, Park JS, Waxman IM, Roy A, Gupta M. Agrawal S, et al. Among authors: feng y. J Clin Pharmacol. 2017 Mar;57(3):394-400. doi: 10.1002/jcph.818. Epub 2016 Sep 27. J Clin Pharmacol. 2017. PMID: 27557786

7

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Agrawal S, et al. Among authors: feng y. J Immunother Cancer. 2016 Nov 15;4:72. doi: 10.1186/s40425-016-0177-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 27879974 Free PMC article.

8

Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.

Bajaj G, Gupta M, Feng Y, Statkevich P, Roy A. Bajaj G, et al. Among authors: feng y. J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11. J Clin Pharmacol. 2017. PMID: 28800166 Free PMC article. No abstract available.

9

Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.

Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, Finckenstein FG, Park JS, Roy A. Feng Y, et al. Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842. Clin Cancer Res. 2017. PMID: 28916617

10

Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.

Feng Y, Wang X, Suryawanshi S, Bello A, Roy A. Feng Y, et al. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):825-834. doi: 10.1002/psp4.12454. Epub 2019 Aug 13. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31334596 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,901 results

Search Page

Filters